
Biorce is a pioneering company revolutionizing drug development through artificial intelligence, positioning itself at the intersection of AI and healthcare. Their flagship product, Jarvis, is the first Clinical AI Assistant designed to streamline and improve clinical trial processes. Jarvis assists with smart study design, protocol development, feasibility analysis, and patient recruitment, aiming to reduce delays and improve outcomes. The company targets biotech, pharma, and CROs, enabling them to cut waste, minimize amendments, and enhance efficiency and precision in medical research. Biorce's mission is driven by the belief that 'hope should never wait,' emphasizing faster and smarter drug development.

Biorce is a pioneering company revolutionizing drug development through artificial intelligence, positioning itself at the intersection of AI and healthcare. Their flagship product, Jarvis, is the first Clinical AI Assistant designed to streamline and improve clinical trial processes. Jarvis assists with smart study design, protocol development, feasibility analysis, and patient recruitment, aiming to reduce delays and improve outcomes. The company targets biotech, pharma, and CROs, enabling them to cut waste, minimize amendments, and enhance efficiency and precision in medical research. Biorce's mission is driven by the belief that 'hope should never wait,' emphasizing faster and smarter drug development.
Headquarters: Barcelona
Product: Aika — explainable AI platform for clinical trial design, feasibility, and regulatory planning
Founded: 2024
Target customers: Pharma, biotech, and CROs
Recent funding stage: Seed
Clinical trial design and execution inefficiencies
2024
Biotechnology
Latest disclosed round recorded as Seed on Dec 3, 2024.
“Backed by investors including Norrsken VC and DST Global”
| Company |
|---|